Differentiated Thyroid Carcinoma
Differentiated thyroid carcinoma (DTC) is papillary or follicular thyroid cancer that retains some features of normal hormone-producing thyroid cells.
Key takeaways
- Most thyroid nodules are benign; ultrasound features and needle sampling identify which require cancer treatment.
- Extent of surgery, radioiodine and thyroid-stimulating hormone suppression depend on recurrence risk rather than one standard pathway.
- Kinase inhibitors are reserved for selected progressive, radioiodine-refractory disease because adverse effects are substantial.
The listings below are not a treatment plan; thyroid oncology should define risk, molecular findings and monitoring.
From nodule to risk category
Ultrasound assesses size, composition, margins, calcification and lymph nodes. Cytology and sometimes molecular testing guide surgery. Final pathology defines subtype, invasion and spread, while thyroglobulin and imaging support follow-up after appropriate treatment.
Treatment across disease stages
Surgery ranges from lobectomy to total thyroidectomy according to tumour and patient factors. Radioiodine benefits selected higher-risk disease, not every small cancer. Progressive metastatic disease may use mutation-directed or multikinase therapy after confirming that observation or local treatment is insufficient.
When to seek urgent care
Seek prompt assessment for a rapidly enlarging neck mass, breathing or swallowing difficulty, coughing blood, new persistent hoarseness, severe weakness or fever during systemic treatment.